Aarhus University Seal / Aarhus Universitets segl

Knud Erik Bach Knudsen

Pre-diagnostic plasma enterolactone concentrations and breast cancer prognosis among postmenopausal Danish women – The Danish Diet, Cancer and Health cohort

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Cecilie Kyrø, Danish Cancer Society Research Centre, Danish Cancer Society, Copenhagen, Denmark., Danmark
  • Louise Hansen, Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen 2100, Denmark., Danmark
  • Kirsten Frederiksen, Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen 2100, Denmark., Ukendt
  • Natalja Nørskov
  • Knud Erik Bach Knudsen
  • Anne Kirstine Eriksen, Danish Cancer Society Research Centre, Danish Cancer Society, Copenhagen, Denmark., Danmark
  • Marianne Holm, Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen 2100, Denmark.
  • ,
  • Anne Tjønneland, Danish Cancer Society Research Center
  • ,
  • Anja Olsen, Danish Cancer Society Research Center, Danmark
Background & aims High intakes of the phytoestrogen lignans and high blood concentrations of its main biomarker, enterolactone, has been associated with a better breast cancer prognosis. We investigated the association between pre-diagnostic plasma concentrations of enterolactone and breast cancer prognosis (i.e. recurrence, breast cancer-specific mortality and all-cause mortality). Methods Plasma and data was available from the Danish Diet, Cancer and Health cohort. Information on treatment and clinical characteristics from registries and clinical databases and both pre-diagnostic and diagnostic plasma measurement of enterolactone on a sub-set. Enterolactone was quantified in plasma using a high-throughput LC−MS/MS method. We followed 1457 breast cancer cases from date of diagnosis and until censoring or end-of-follow-up (median 9 years), during this time 404 died (250 of breast cancer) and 267 experienced recurrence. Cox proportional hazards models were used to estimate hazard ratios (HR) with 95% confidence intervals (CI). Results Plasma enterolactone were borderline significantly associated with lower breast cancer-specific mortality (HRdoubling = 0.93, 95% CI:0.86, 1.00, P = 0.0501), but not associated with all-cause mortality (HRdoubling = 0.95, 95% CI:0.89, 1.01) and recurrence (HRdoubling = 0.96, 95% CI: 0.89, 1.04) in the models adjusted for smoking, schooling, BMI, physical activity and use of menopausal hormones. Adjusting further for clinical characteristics and treatment did not change the results considerably. In the sensitivity analyses, an inverse association was found with all-cause and breast cancer-specific mortality for those where blood was collected ≤5 years before diagnosis. Conclusions Overall, no clear association was found between pre-diagnostic plasma concentrations of enterolactone and breast cancer prognosis.
OriginalsprogEngelsk
TidsskriftClinical Nutrition
Vol/bind37
Nummer6
Sider (fra-til)2217-2225
ISSN0261-5614
DOI
StatusUdgivet - dec. 2018

Se relationer på Aarhus Universitet Citationsformater

Projekter

ID: 120490188